Review of upcoming and currently available anti-obesity drugs in Europe
DOI:
https://doi.org/10.12775/JEHS.2023.30.01.005Keywords
obesity., pharmacology, liraglutide, semaglutide, tirzepatideAbstract
Obesity is a chronic metabolic disease currently holding status of an epidemic. Number of patients suffering from this condition has been steadily increasing for over 50 years. Complications and comorbidities related to obesity, such as hypertension, diabetes mellitus type 2, coronary artery disease and dyslipidemia are currently the main causes of death in Europe. Therefore, effective anti-obesity treatment as a pharmacological support for weight loss is highly recommended in overweight and obese patients as a therapeutic and preventive measure. This review focuses on selected therapeutic options available for clinicians in Europe.
References
Organisation for Economic Cooperation and Development, Main causes of mortality, https://www.oecd-ilibrary.org/sites/82129230-en/1/3/2/1/4/index.html?itemId=/content/publication/82129230-en&_csp_=e7f5d56a7f4dd03271a59acda6e2be1b&itemIGO=oecd&itemContentType=book, accessed on April 17 2023.
Khalid F, Siddique A, Siddiqui JA, Panhwar G, Singh S, Anwar A, Hashmi AA. Correlation Between Body Mass Index and Blood Pressure Levels Among Hypertensive Patients: A Gender-Based Comparison. Cureus. 2020 Oct 15;12(10):e10974. doi: 10.7759/cureus.10974. PMID: 33101788; PMCID: PMC7575319.
Gray N, Picone G, Sloan F, Yashkin A. Relation between BMI and diabetes mellitus and its complications among US older adults. South Med J. 2015 Jan;108(1):29-36. doi: 10.14423/SMJ.0000000000000214. PMID: 25580754; PMCID: PMC4457375.
University of Oxford, Moderate obesity takes years off life expectancy, https://www.ox.ac.uk/news/2009-03-18-moderate-obesity-takes-years-life-expectancy, accessed on April 17 2023.
Dougan MM, Hankinson SE, Vivo ID, Tworoger SS, Glynn RJ, Michels KB. Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. Int J Cancer. 2015 Aug 1;137(3):625-37. doi: 10.1002/ijc.29427. Epub 2015 Feb 5. PMID: 25641700; PMCID: PMC5241095.
Chen Y, Liu L, Wang X, Wang J, Yan Z, Cheng J, Gong G, Li G. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1395-408. doi: 10.1158/1055-9965.EPI-13-0042. Epub 2013 May 22. PMID: 23697611.
Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, Wu AH, Ward MH, Casson AG, Murray LJ, Corley DA, Nyrén O, Pandeya N, Vaughan TL, Chow WH, Gammon MD. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012 Dec;41(6):1706-18. doi: 10.1093/ije/dys176. Epub 2012 Nov 12. PMID: 23148106; PMCID: PMC3535758.
Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer. 2012 Sep;48(14):2137-45. doi: 10.1016/j.ejca.2012.02.063. Epub 2012 Mar 23. PMID: 22446023.
Wang F, Xu Y. Body mass index and risk of renal cell cancer: a dose-response meta-analysis of published cohort studies. Int J Cancer. 2014 Oct 1;135(7):1673-86. doi: 10.1002/ijc.28813. Epub 2014 Mar 6. PMID: 24615287.
Li L, Gan Y, Li W, Wu C, Lu Z. Overweight, obesity and the risk of gallbladder and extrahepatic bile duct cancers: A meta-analysis of observational studies. Obesity (Silver Spring). 2016 Aug;24(8):1786-802. doi: 10.1002/oby.21505. Epub 2016 Jul 9. PMID: 27392541.
Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016 May 7;387(10031):1947-56. doi: 10.1016/S0140-6736(16)00271-3. Epub 2016 Feb 10. PMID: 26868660.
Chao AM, Quigley KM, Wadden TA. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest. 2021 Jan 4;131(1):e140065. doi: 10.1172/JCI140065. PMID: 33393504; PMCID: PMC7773341.
Jean-Michel Oppert, Alice Bellicha, Cécile Ciangura, Physical activity in management of persons with obesity, European Journal of Internal Medicine, Volume 93, 2021, Pages 8-12, ISSN 0953-6205, https://doi.org/10.1016/j.ejim.2021.04.028.
European Medicines Agency, Sibutramine, https://www.ema.europa.eu/en/medicines/human/referrals/sibutramine, accessed on April 17, 2023.
European Medicines Agency, https://www.ema.europa.eu/en/documents/referral/sibutramine-article-107-procedure-annex-i-ii-iii_pl.pdf, accessed on April 17, 2023.
U.S. Food and Drug Administration, Meridia, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020632s034s035lbl.pdf, accesed, on April 17, 2023.
Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev. 2008 Jul;9(4):378-87. doi: 10.1111/j.1467-789X.2007.00425.x. Epub 2007 Nov 23. PMID: 18034790.
Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP; SCOUT Investigators. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012 Jun;14(6):523-30. doi: 10.1111/j.1463-1326.2011.01554.x. Epub 2012 Jan 18. PMID: 22192338.
European Medicines Agency, European Medicines Agency recommends suspension of marketing authorisation for sibutramine, https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-suspension-marketing-authorisation-sibutramine, accessed on April 17 2023.
Danish Medicines Agency, List of illegal sibutramine-containing weight-loss products, https://laegemiddelstyrelsen.dk/en/pharmacies/medicines-imported-from-abroad/are-you-considering-buying-slimming-pills/list-of-illegal-sibutramine-containing-weight-loss-products/, accessed on April 17, 2023.
Barak LS, Salahpour A, Zhang X, Masri B, Sotnikova TD, Ramsey AJ, Violin JD, Lefkowitz RJ, Caron MG, Gainetdinov RR. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol. 2008 Sep;74(3):585-594. doi: 10.1124/mol.108.048884. Epub 2008 Jun 4. PMID: 18524885; PMCID: PMC3766527.
National Center for Biotechnology Information. "PubChem Compound Summary for CID 4771, Phentermine" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Phentermine. Accessed 17 April, 2023.
U.S. Food and Drug Administration, Adipex, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf accesses on April 17, 2023.
The European Commission (EC) has decided that various anorectics are to be withdrawn in the EU. React. Wkly. 790, 2 (2000). https://doi.org/10.2165/00128415-200007900-00003
European Medicines Agency, Qsiva, https://www.ema.europa.eu/en/medicines/human/EPAR/qsiva, accessed on April 17, 2023.
The European Commission (EC) has decided that various anorectics are to be withdrawn in the EU. React. Wkly. 790, 2 (2000). https://doi.org/10.2165/00128415-200007900-00003
European Medicines Agency, Mysimba product information, https://www.ema.europa.eu/en/documents/product-information/mysimba-epar-product-information_en.pdf, accessed on April 17, 2023.
Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020 Apr;86(4):646-667. doi: 10.1111/bcp.14210. Epub 2020 Feb 4. PMID: 31918448; PMCID: PMC7098870.
European Medicines Agency, Xenical, https://www.ema.europa.eu/en/documents/product-information/xenical-epar-product-information_pl.pdf, aceessed on April 17 2023.
Fagot-Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Ducimetière P, Eschwège E. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol. 1998 Oct;27(5):808-13. doi: 10.1093/ije/27.5.808. PMID: 9839737.
Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother. 2007 Aug;8(11):1733-42. doi: 10.1517/14656566.8.11.1733. PMID: 17685889.
Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol. 1996 Jul;36(7):647-53. doi: 10.1002/j.1552-4604.1996.tb04230.x. PMID: 8844448.
Medycyna praktyczna, Orlistat, https://www.mp.pl/pacjent/leki/subst.html?id=635, accessed on April 17, 2023.
McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002 Jul;22(7):814-22. doi: 10.1592/phco.22.11.814.33627. PMID: 12126214.
Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998 Jul 18;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4. PMID: 9683204.
Hollywood A, Ogden J. Taking Orlistat: Predicting Weight Loss over 6 Months. J Obes. 2011;2011:806896. doi: 10.1155/2011/806896. Epub 2010 Nov 11. PMID: 21113309; PMCID: PMC2989378.
Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab. 2011 Apr;15(2):99-104. doi: 10.4103/2230-8210.81938. PMID: 21731866; PMCID: PMC3125014.
Bansal AB, Al Khalili Y. Orlistat. [Updated 2022 Dec 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542202/
Humayun Y, Ball KC, Lewin JR, Lerant AA, Fülöp T. Acute oxalate nephropathy associated with orlistat. J Nephropathol. 2016 Apr;5(2):79-83. doi: 10.15171/jnp.2016.14. Epub 2016 Mar 29. PMID: 27152294; PMCID: PMC4844913.
European Medicines Agency, Saxenda, https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda, accessed on April 17, 2023.
Sisson EM. Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy. 2011 Sep;31(9):896-911. doi: 10.1592/phco.31.9.896. PMID: 21923591.
Tilinca MC, Tiuca RA, Burlacu A, Varga A. A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review. Medicina (Kaunas). 2021 Jun 29;57(7):669. doi: 10.3390/medicina57070669. PMID: 34209532; PMCID: PMC8307742.
Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Adv Exp Med Biol. 2021;1307:171-192. doi: 10.1007/5584_2020_496. PMID: 32077010.
Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 5:S42-7. doi: 10.1038/sj.ijo.0801912. PMID: 11840214.
Ten Kulve JS, Veltman DJ, van Bloemendaal L, Groot PF, Ruhé HG, Barkhof F, Diamant M, Ijzerman RG. Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. J Endocrinol. 2016 Apr;229(1):1-12. doi: 10.1530/JOE-15-0461. Epub 2016 Jan 14. PMID: 26769912.
Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep. 2021 Mar;10(1):14-30. doi: 10.1007/s13679-020-00422-w. Epub 2021 Jan 6. PMID: 33410104; PMCID: PMC7787121.
Alruwaili H, Dehestani B, le Roux CW. Clinical Impact of Liraglutide as a Treatment of Obesity. Clin Pharmacol. 2021 Mar 11;13:53-60. doi: 10.2147/CPAA.S276085. PMID: 33732030; PMCID: PMC7958997.
Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006 Mar;49(3):452-8. doi: 10.1007/s00125-005-0126-y. Epub 2006 Jan 31. PMID: 16447057.
Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 May;43(5):1085-1093. doi: 10.2337/dc19-1745. Epub 2020 Mar 5. PMID: 32139381; PMCID: PMC7171937.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. PMID: 26132939.
European Medicines Agency, Wegovy, https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy, accessed on April 17, 2023.
Anam M, Maharjan S, Amjad Z, Abaza A, Vasavada AM, Sadhu A, Valencia C, Fatima H, Nwankwo I. Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). Cureus. 2022 Dec 16;14(12):e32610. doi: 10.7759/cureus.32610. PMID: 36654602; PMCID: PMC9840940.
Garvey, W.T., Batterham, R.L., Bhatta, M. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28, 2083–2091 (2022). https://doi.org/10.1038/s41591-022-02026-4
van Ruiten CC, Veltman DJ, Nieuwdorp M, IJzerman RG. Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide. Front Endocrinol (Lausanne). 2022 May 4;13:863592. doi: 10.3389/fendo.2022.863592. PMID: 35600575; PMCID: PMC9114766.
Pereira MJ, Eriksson JW. Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity. Drugs. 2019 Feb;79(3):219-230. doi: 10.1007/s40265-019-1057-0. PMID: 30701480; PMCID: PMC6394798.
Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017 Sep;19(9):1276-1288. doi: 10.1111/dom.12954. Epub 2017 May 31. PMID: 28345814; PMCID: PMC5575470.
European Medicines Agency, Mounjaro, https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro, accessed on April 17, 2023.
Melissa K Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Kevin Duffin, Zvonko Milicevic, Axel Haupt, Deborah A Robins, Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes, The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 2, February 2021, Pages 388–396, https://doi.org/10.1210/clinem/dgaa863
Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Tirzepatide Once Weekly for the Treatment of Obesity, N Engl J Med 2022; 387:205-216, DOI: 10.1056/NEJMoa2206038
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Patryk Gryszkiewicz, Jakub Szydło, Jakub Starownik, Jan Wędrychowski, Bernadeta Zabielska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 903
Number of citations: 0
